Literature DB >> 20951313

Somatic mutations of signaling genes in non-small-cell lung cancer.

Heather R Sanders1, Maher Albitar.   

Abstract

Lung cancer is the leading cause of cancer-related deaths, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of cases. A significant proportion of NSCLC cases are not diagnosed until a late stage, when aggressive treatments are required but often prolong survival only modestly. Recent advances in molecular characterization of NSCLC have enabled identification of numerous cell growth and proliferation pathways that are disrupted in these tumors. This knowledge has provided insight into the mechanisms of tumor development in various histologic subtypes of NSCLC and has pointed the way toward targeted treatment strategies. In this review, we highlight literature findings of somatic mutations in genes involved in cell growth and proliferation that are commonly found in the various subtypes of NSCLC, and we discuss how these findings may relate to treatment strategies.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951313     DOI: 10.1016/j.cancergencyto.2010.07.134

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  18 in total

1.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

2.  The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.

Authors:  Hui Ren; Mingwei Chen; Ping Yue; Hui Tao; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Lett       Date:  2012-07-07       Impact factor: 8.679

3.  TASK-1 induces gefitinib resistance by promoting cancer initiating cell formation and epithelial-mesenchymal transition in lung cancer.

Authors:  Xing-Guang Wang; Na-Xin Yuan; Xin-Peng Li; Fang-Fang Chen
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

4.  Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.

Authors:  Jian Liu; Sung-Nam Cho; San-Pin Wu; Nili Jin; Seyed Javad Moghaddam; Jennifer L Gilbert; Ignacio Wistuba; Francesco J DeMayo
Journal:  Lung Cancer       Date:  2017-08-05       Impact factor: 5.705

Review 5.  EGFR mutation status in brain metastases of non-small cell lung carcinoma.

Authors:  Fanny Burel-Vandenbos; Damien Ambrosetti; Michael Coutts; Florence Pedeutour
Journal:  J Neurooncol       Date:  2012-10-20       Impact factor: 4.130

6.  Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer.

Authors:  Shih-Hsin Hsiao; Sey-En Lin; Yu-Ting Chou; Jinn-Li Wang; Chi-Li Chung; Ming-Chih Yu; Chia-Lang Fang; Hsin-Lun Lee; Ling-Ling Chiang; H Eugene Liu; Cheng-Wen Wu
Journal:  Mol Clin Oncol       Date:  2013-12-23

7.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

Authors:  G R Blumenschein; E F Smit; D Planchard; D-W Kim; J Cadranel; T De Pas; F Dunphy; K Udud; M-J Ahn; N H Hanna; J-H Kim; J Mazieres; S-W Kim; P Baas; E Rappold; S Redhu; A Puski; F S Wu; P A Jänne
Journal:  Ann Oncol       Date:  2015-02-26       Impact factor: 32.976

8.  Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition.

Authors:  H-O Jin; S-E Hong; S-H Woo; J-H Lee; T-B Choe; E-K Kim; W-C Noh; J-K Lee; S-I Hong; J-I Kim; I-C Park
Journal:  Cell Death Dis       Date:  2012-06-07       Impact factor: 8.469

Review 9.  Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Authors:  Jill Wykosky; Tim Fenton; Frank Furnari; Webster K Cavenee
Journal:  Chin J Cancer       Date:  2011-01

10.  MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer.

Authors:  Jia-Lin Shang; Shao-Bo Ning; Ying-Yi Chen; Tian-Xiang Chen; Jian Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-06-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.